GleamWall
中文EN

MGRX MANGOCEUTICALS, INC.

Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1938046 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-35.6%
TTM net income YoY44.3%
TTM EPS YoY80.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin52.9%
Operating margin-2,608.1%
Net margin-3,673.7%
FCF margin—
EBITDA margin-2,607.7%

Returns

ROE-82.3%
ROA-69.8%
ROIC (approx.)-48.2%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio1.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-45.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$69,503$68,757$67,864$94,360$84,246$168,109$109,306$105,247
Cost of revenue$8,813$10,437$8,218$8,511$2,359$18,815$24,737$21,331
Gross profit$38,397$44,215$29,001$47,475$50,899$89,948$62,064$80,103
SG&A expense$428,955$256,095$1.05M$657,190$311,379$1.25M$1.54M$854,054
Operating income-$3.31M-$1.03M-$3.13M-$367,739-$7.26M-$5.27M-$4.58M-$1.68M
Interest expense$1,099——$19,663$75,850$21,700-$13,700—
Pretax income-$3.55M-$1.31M-$3.40M-$2.77M-$7.62M-$5.42M-$4.84M-$1.95M
Net income-$3.55M-$1.31M-$3.40M-$2.77M-$7.62M-$5.42M-$4.84M-$1.95M
EBITDA-$3.31M-$1.03M-$3.13M-$367,485-$7.26M-$5.27M-$4.58M-$1.67M
EPS (basic)-0.19-0.09-0.22—-0.69-0.57-1.12—
EPS (diluted)-0.19-0.09-0.22—-0.69-0.57-1.12—
Weighted avg. shares (diluted)20.42M17.12M16.48M—11.52M9.98M4.59M—
Balance sheet
Cash & equivalents$659,258$228,688$174,562$1.49M$481,281$101,019$76,496$58,653
Current assets$1.49M$245,687$212,472$1.55M$598,223$117,961$176,652$75,595
PP&E, net$1,037$1,292$1,544$1,794$2,049$2,304$2,556$2,806
Intangibles$13.35M$13.65M$13.94M$14.23M$15.92M$20.69M$21.53M$15.23M
Total assets$15.11M$14.17M$14.45M$16.09M$16.53M$20.84M$21.75M$15.37M
Current liabilities$1.16M$1.40M$737,606$890,568$804,275$1.60M$1.50M$1.43M
Total liabilities$1.41M$1.65M$974,571$890,568$804,275$1.60M$1.50M$1.43M
Shareholders' equity$11.08M$12.53M$13.48M$15.20M$15.73M$19.24M$20.25M$13.95M
Shares outstanding21.57M18.02M16.97M15.89M13.88M10.64M7.14M3.25M
Cash flow statement
Operating cash flow-$1.15M-$260,506-$1.31M-$1.08M-$1.24M-$1.26M-$2.27M-$1.13M
Investing cash flow———————$0
Financing cash flow$1.58M——$2.08M$1.62M$1.28M$2.29M$1.12M
Depreciation & amortization$255$252$250$254$256$252$250$7,935
Stock-based compensation$1.05M$12,417$1.09M-$33,471$1.10M$50,979$50,979$50,979

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.